The Hellenic Society of Gastroenterology \[[@ref1]\] recently published the National consensus on *Helicobacter pylori* (*H. pylori*) infection, following the necessity of a uniform approach to yield optimal eradication rates. As implied by the recent Maastricht V/Florence consensus \[[@ref2]\], an "add-on" strategy regarding antibiotics was adapted to overleap the increasing antibiotic resistance, combined with the absence of bismuth-containing drugs, thus perpetuating a "vicious circle" and emerging novel approaches in treatment models with a targeted pathophysiological perspective. Importantly, parameters connected with the multidrug resistance include the formation of *H. pylori*-related biofilms, suggesting the introduction of novel anti-biofilm therapeutic approaches using anti-biofilm agents \[[@ref3]\].

A unanimous suggestion (Statement 10) proposed that *H. pylori* culture or molecular techniques should be conducted to evaluate the antimicrobial susceptibility. Nevertheless, those methods are characterized by limited availability in most regions. On the other hand, recent data imply a potential benefit of vitamin D (vitD) for *H. pylori* infection treatment, related to the vitD-receptor's (VDR) antimicrobial role \[[@ref4]-[@ref6]\]. VDR, stimulated by the active *H. pylori* infection, induces human β-defensins, which in high concentrations suppress *H. pylori* biofilm activity \[[@ref3]\]; subtle or strong activation of VDR, due to vitD absence or adequacy, could contribute or not to *H. pylori* acclimatization, morbidity, resistance, and survival \[[@ref3]\]. Additionally, vitD seems to act directly as an antibacterial agent through stimulation of defensins and cathelicidins, and vitD upregulated protein 1 (VDP1). possesses an *H. pylori-*specific antimicrobial ability, indicating a promising therapeutic potential \[[@ref7],[@ref8]\]. Moreover, studies in mouse models revealed a protective role of a VDP1 against *H. pylori-*related gastric cancer \[[@ref9]\]. Clinical studies concluded that vitD had a protective role against *H. pylori* infection and suggested its deficiency as a distinct risk factor in the failure of eradication treatment, while a recent meta-analysis concluded that vitD supplementation could change the effectiveness of eradication regimens \[[@ref10]\]. Therefore, a National multicenter study has recently been inaugurated to elucidate the relationship between vitD and *H. pylori* infection and the potential beneficial effect of vitD supplementation during eradication treatment.

Conflict of Interest: None

401 General Military Hospital of Athens, Greece; Aristotle University of Thessaloniki, Macedonia, Greece; Ippokration Hospital, Aristotle University of Thessaloniki, Macedonia, Greece; University of Zurich, Switzerland
